Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:02 PM ET 5/20/2013
Last 10 Quotes:
What's This?
| Fiscal Q1 Ending 03/13 |
Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
|
Sales/Revenue |
8,059,000 | 8,526,000 | 9,040,000 | 8,870,000 | 8,511,000 |
Cost of Goods Sold (COGS) incl. D&A |
3,314,000 | 3,674,000 | 3,700,000 | 3,575,000 | 3,460,000 |
COGS excluding D&A |
2,539,000 | 2,874,000 | 2,884,000 | 2,733,000 | 2,627,000 |
Depreciation & Amortization Expense |
775,000 | 800,000 | 816,000 | 842,000 | 833,000 |
Gross Income |
4,745,000 | 4,852,000 | 5,340,000 | 5,295,000 | 5,051,000 |
SG&A Expense |
3,284,000 | 3,712,000 | 3,332,000 | 3,528,000 | 3,297,000 |
Research & Development |
1,155,000 | 1,358,000 | 1,149,000 | 1,239,000 | 1,176,000 |
Other SG&A |
2,129,000 | 2,354,000 | 2,183,000 | 2,289,000 | 2,121,000 |
Other Operating Expense |
41,000 | 80,000 | 50,000 | 265,000 | 59,000 |
Unusual Expense |
105,000 | NA | 131,000 | 275,000 | 121,000 |
Non Operating Income/Expense |
169,000 | 260,000 | 317,000 | 360,000 | 632,000 |
Interest Expense |
157,000 | 146,000 | 135,000 | 133,000 | 139,000 |
Gross Interest Expense |
157,000 | 146,000 | 135,000 | 133,000 | 139,000 |
Pretax Income |
1,344,000 | 251,000 | 2,060,000 | 1,479,000 | 2,087,000 |
Income Tax |
311,000 | -197,000 | 462,000 | 373,000 | 496,000 |
Equity in Affiliates |
11,000 | -10,000 | -1,000 | 115,000 | 289,000 |
Consolidated Net Income |
1,044,000 | 438,000 | 1,597,000 | 1,221,000 | 1,880,000 |
Minority Interest Expense |
40,000 | 28,000 | 38,000 | 50,000 | 53,000 |
Net Income |
1,004,000 | 410,000 | 1,559,000 | 1,171,000 | 1,827,000 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
NA | NA | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
1,004,000 | 410,000 | 1,559,000 | 1,171,000 | 1,827,000 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
1,004,000 | 410,000 | 1,559,000 | 1,171,000 | 1,827,000 |
EPS (basic) |
0.76 | 0.31 | 1.18 | 0.89 | 1.38 |
EBITDA |
2,195,000 | 1,860,000 | 2,774,000 | 2,344,000 | 2,528,000 |
Depreciation & Amortization Expense |
775,000 | 800,000 | 816,000 | 842,000 | 833,000 |
Common Shares Outstanding |
1,322,200 | 1,319,500 | 1,318,400 | 1,319,300 | 1,321,200 |
Basic Shares Outstanding |
1,322,200 | 1,319,500 | 1,318,400 | 1,319,300 | 1,321,200 |
Diluted Shares Outstanding |
1,322,200 | NA | NA | NA | NA |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.76 | 0.31 | 1.18 | 0.89 | 1.38 |
*Figures in thousands of U.S. Dollars except shares outstanding.
